KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.

Mathilde Moreau, Emily Alouani, Clémence Flecchia, Antoine Falcoz, Claire Gallois, Edouard Auclin, Thierry André, Romain Cohen, Antoine Hollebecque, Anthony Turpin, Simon Pernot, Thérèse Masson, Frederic Di Fiore, Marie Dutherge, Thibault Mazard, Vincent Hautefeuille, Jean-Luc Van Laethem, Christelle De la Fouchardière, Géraldine Perkins, Meher Ben-Abdelghani, Francesco Sclafani, Thomas Aparicio, Stefano Kim, Dewi Vernerey, Julien Taieb, Rosine Guimbaud, David Tougeron

Eur J Cancer 202 114033

PMID38537314
PMCID-
DOI10.1016/j.ejca.2024.114033
发表日期2024-03-27
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

BACKGROUND: One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer. However, few studies have compared ICI with CT in other advanced dMMR/MSI-H digestive tumors. METHODS: In this multicenter study, we included patients with advanced dMMR/MSI-H non-colorectal digestive tumors treated with chemotherapy and/or ICIs. Patients were divided retrospectively into two groups, a CT group and an immunotherapy (IO) group. The primary endpoint was progression-free survival (PFS). A propensity score approach using the inverse probability of treatment weighting (IPTW) method was applied to deal with potential differences between the two groups. RESULTS: 133 patients (45.1/27.1/27.8% with gastric/small bowel/other carcinomas) were included. The majority of patients received ICI in 1st (29.1%) or 2nd line (44.4%). The 24-month PFS rates were 7.9% in the CT group and 71.2% in the IO group. Using the IPTW method, IO treatment was associated with better PFS (HR=0.227; 95% CI 0.147-0.351; p < 0.0001). The overall response rate was 26.3% in the CT group versus 60.7% in the IO group (p < 0.001) with prolonged duration of disease control in the IO group (p < 0.001). In multivariable analysis, predictive factors of PFS for patients treated with IO were good performance status, absence of liver metastasis and prior primary tumor resection, whereas no association was found for the site of the primary tumor. CONCLUSIONS: In the absence of randomized trials, our study highlights the superior efficacy of ICI compared with standard-of-care therapy in patients with unresectable or metastatic dMMR/MSI-H non-colorectal digestive cancer, regardless of tumor type, with acceptable toxicity.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。